Abstract
Perioperative administration of dexamethasone may augment recurrence and mortality after tumor resection possibly by immunosuppression, which, unfortunately, has never been noted. We therefore carried out a retrospective study in rectal cancer to validate the hypothesis. Five hundreds and fifteen patients with stage I to III rectal cancers who underwent a curative resection from June 2007 and June 2011 were enrolled in the current study. Patients who had been given intravenous (IV) dexamethasone (4-10 mg) postoperatively and/or intraoperatively were assigned to dexamethasone group. The outcome of dexamethasone group and non-dexamethasone group were compared. The primary outcome was disease-free survival (DFS) and overall survival (OS). dexamethasone group had significant lower three-year DFS (62.3% vs 71.8%, P = 0.026) and OS (74.1% vs 82.9%, P = 0.031) rate in comparison to non-dexamethasone group, the hazard ratios (HRs) of which were 1.59 (95% CI 1.05-2.39, P = 0.028) and 1.77 (95% CI 1.05-3.01, P = 0.034), respectively. Multivariate analysis revealed that administration of systemic dexamethasone were independently associated with DFS [adjusted HR 1.60 (95% CI 1.03-2.49, p = 0.039)], but for OS, dexamethasone didn't remain s...Continue Reading
References
Mar 1, 1992·Journal of Neuroscience Research·C H LangeveldJ J Heimans
Jan 1, 1987·European Journal of Clinical Pharmacology·M E BradyC T Bauguess
Jan 1, 1984·Experimental Cell Biology·R I Freshney
Sep 15, 1982·Cancer·N ThatcherD Crowther
Jan 1, 1980·Journal of Surgical Oncology·J Lundy
Apr 1, 1994·Neurology·C J VechtW L van Putten
May 13, 1993·The New England Journal of Medicine·O R BuschJ Jeekel
Jan 1, 1994·American Journal of Surgery·T A ColacchioL W Hildebrandt
Jun 1, 1993·Cellular Immunology·J E KunickaG Goldstein
Jan 1, 1996·The Journal of Allergy and Clinical Immunology·L M SchwiebertL A Schwiebert
Nov 10, 1998·Journal of Cellular Physiology·S LiC Sell
May 30, 2002·EMBO Reports·Gitali GanguliBohdan Wasylyk
Oct 7, 2003·Annals of Surgical Oncology·Guy Shakhar, Shamgar Ben-Eliyahu
Jan 1, 2005·Current Opinion in Oncology·Olga Frankfurt, Steven T Rosen
Nov 9, 2006·Annals of Surgical Oncology·Guy ShakharShamgar Ben-Eliyahu
Apr 1, 2008·BMC Cancer·Bruce D Keith
Jun 15, 2011·British Journal of Anaesthesia·G S De OliveiraR J McCarthy
Nov 23, 2011·Anesthesia and Analgesia·Renchun LaiMinshan Chen
Jan 25, 2012·Current Opinion in Anaesthesiology·Trevor Kavanagh, Donal J Buggy
Apr 10, 2012·Cellular Immunology·Kristin A BushHerbert L Mathews
Sep 5, 2012·American Journal of Surgery·Kerem KaramanMusa Akoglu
Jan 4, 2013·British Journal of Anaesthesia·A Heaney, D J Buggy
May 23, 2013·Cancer Letters·Shagufta KhanJun Ling
Citations
Nov 20, 2015·Current Medical Research and Opinion·Brittany A MerkAshraf S Habib
Mar 27, 2016·Annals of Surgical Oncology·Stephen T McSorleyDonald C McMillan
Aug 10, 2016·Surgery Research and Practice·Dario BugadaGuido Fanelli
Mar 9, 2018·Anesthesia and Analgesia·Wen-Wen HuangDaqing Ma
Oct 9, 2019·Der Anaesthesist·B Sinner
Jan 2, 2020·Cancers·Emma Rosenkrantz HölmichIsmail Gögenur
Mar 22, 2019·BMC Cancer·Myoung Hwa KimYoung Chul Yoo
Apr 15, 2020·International Journal of Molecular Sciences·Silvia ZappavignaMichele Caraglia
Jul 16, 2020·Investigative and Clinical Urology·Shiyu MaoXudong Yao
Jan 4, 2021·Surgery Today·Fausto PetrelliEmanuele Rausa
Jul 1, 2019·British Journal of Anaesthesia·T WallD J Buggy
Oct 2, 2021·Der Anaesthesist·Peter KienbaumPeter Kranke